Insight Innovation: „Klug, schön und gesund“: bis zu 25.000 Dollar für ein optimiertes Baby

Munich has seen a groundbreaking development in reproductive medicine – the use of polygenic embryo screening to create Aurea, the first child known to have undergone this process. The technique involves examining an embryo for various genetic variants while it remains frozen after being created through artificial fertilization. This method does not alter the embryo's genetic makeup but instead provides statistical risk assessments for certain diseases and traits.

Several start-ups in the United States offer such tests, promising benefits ranging from reduced Alzheimer's risk to higher IQ scores. However, these companies also evaluate embryos based on factors like body size, Body Mass Index, ADHD, and intelligence. Prominent investors, including Sam Altman of AI company OpenAI, are increasingly drawn to this emerging field, leading to polarized opinions among geneticists.

While some argue that the commercialization of the technology is premature, Yves Moreau, a geneticist and bioinformatician from KU Leuven, Belgium, contends that there is still too much gap between the marketed claims and the actual effectiveness of the procedure. As the world stands on the brink of a new era in human evolution, one must wonder whether polygenic embryo screening opens the door to a new age of genetic selection or if it merely marks a significant step forward in reproductive medicine.